Palatin Announces Presentation at the Eyecelerator@AAO 2022 Conference

Overview of Development Pipeline of Melanocortins for Treatment of Ocular Conditions and Role in Resolving Inflammation PL9643 Phase 3 Study Results in Dry Eye Disease Currently Expected 2Q 2023 Palatin Progressing Development Programs in Retinal and Front-of-the-Eye Indications Supported...